CancerIQ Expands Diagnostic Network with Addition of geneType™ PRS Test from Rhythm Biosciences

PartnershipgeneType™ PRS TestPositive

AI Analysis

Summary

CancerIQ announced that Rhythm Biosciences' geneType™ Cancer Risk Assessment test is now available on the CancerIQ platform, which includes 60+ health systems. This partnership expands the diagnostic tools available to providers through CancerIQ's network.

Importance:5/10

Sentiment:

0.60

diagnosticpartnershipcancer risk assessmentnetwork expansion

Related Companies

$RYTM

Read the original article

Published by PR Newswire Biotech on June 4, 2026 11:37 AM

Read Original